Tumor treating fields enhance anti-PD therapy by improving CCL2/8 and CXCL9/CXCL10 expression through inducing immunogenic cell death in NSCLC models
TTFields enhance the effectiveness of anti-PD immunotherapy by improving CD4<sup>+</sup> T cells and CD8<sup>+</sup> T infiltration via inducing ICD to increase CCL2/8 and CXCL9/CXCL10 expression of tumor cells. This study provides theoretical basis and new insights for evaluating the effectiveness of TTFields combined with anti-PD therapy for NSCLC.
Authors
- Jingjing Feng (ORCID: https://orcid.org/0000-0002-1607-4499)
- Yingying Wang (ORCID: https://orcid.org/0000-0001-7607-8136)
- Yun Hu (ORCID: https://orcid.org/0000-0001-5597-9234)
- Yuanzhen Suo (ORCID: https://orcid.org/0000-0001-9027-2496)
- Minghao Li (ORCID: https://orcid.org/0000-0002-3516-3702)
- Ying Yue (ORCID: https://orcid.org/0000-0001-7657-6020)
- Jing Yu (ORCID: https://orcid.org/0009-0009-3028-9312)
- Wei Lin (ORCID: https://orcid.org/0000-0001-6886-2502)
Institutions
- WuXi AppTec (China) (CN)
- Deyang Stomatological Hospital (CN)
- Shandong Provincial Hospital (CN)
- Liuyang City Maternal and Child Health Hospital (CN)
- Shandong Provincial QianFoShan Hospital (CN)
- Shandong First Medical University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1186/s12885-025-13859-w
- Citations
- 8
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 8.36
Funders
- Natural Science Foundation of Shandong Province